CLINICAL STUDY PROTOCOL - Moderna
understanding of SARS-CoV-2 infection and COVID-19, including analyses related to the immunology of this or other vaccines, detection of viral infection, and clinical conduct. Study Design and Methodology: This is a Phase 3, randomized, stratified, observer-blind, placebo-controlled study to evaluate the efficacy, safety, and
Download CLINICAL STUDY PROTOCOL - Moderna
Information
Domain:
Source:
Link to this page:
Documents from same domain
Vaccination Provider Fact Sheet | EUA | Moderna COVID-19 ...
www.modernatx.comPrimary Series: Each primary series dose of the Moderna COVID-19 Vaccine is 0.5 mL. The Moderna COVID-19 Vaccine is administered as a primary series of two doses (0.5 mL each) ... See this Fact Sheet for instructions for preparation and administration. This Fact Sheet may have . Revised: Dec/9/2021 2
COVID-19 Vaccine (mRNA-1273) - Moderna
www.modernatx.comNov 16, 2020 · Pediatric respiratory syncytial virus (RSV) vaccine Future respiratory combo Worldwide mRNA-1189 Epstein-Barr virus (EBV) vaccine Worldwide mRNA-1851 Influenza H7N9vaccine ... Presentation of older adults Phase 1 data October 22, 2020 Phase 3 COVE study completed enrollment of 30,000 participants Sept 29, 2020 Publication of older adults …
Storage Handling - Moderna
www.modernatx.comStorage and Handling The information in this Fact Sheet supersedes the information on the vial and carton labels. During storage, minimize exposure to room light. The Moderna COVID-19 Vaccine multiple-dose vials are stored frozen between -50º to -15ºC (-58º to 5ºF). Store in the original carton to protect from light.
WHITE PAPER mRNA Vaccines - Moderna
www.modernatx.comsyringe Investment decisions in production facility (3-5yr lead time) Standardized (mg scale) Standardized (kg scale) Standardized multiproduct facility (kg scale) mRNA vaccine DNA vaccine: Bespoke facility ($100mm-$1bn) (tonne scale) Specialized delivery system Standard needle &
US00000010898574B220210126
www.modernatx.comTitle: US00000010898574B220210126 Subject: 00780001 Created Date: 20210106010406Z
IMPORTANT PRESCRIBING INFORMATION Booster Dose …
www.modernatx.comreport vaccine administration errors to the Vaccine Adverse Event Reporting System (VAERS). See the Fact Sheet for Vaccination Providers for reporting instructions. Additional Resources To access the most recent Moderna COVID-19 Vaccine Fact Sheets, please scan the QR code or
Vaccine Recipient Fact Sheet | EUA | Moderna COVID-19 …
www.modernatx.comEMERGENCY USE AUTHORIZATION (EUA) OF THE MODERNA COVID-19 VACCINE TO PREVENT CORONAVIRUS DISEASE 2019 (COVID-19) IN INDIVIDUALS 18 YEARS OF AGE AND OLDER You are being offered the Moderna COVID-19 Vaccine to prevent Coronavirus Disease 2019 (COVID-19) caused by SARS-CoV-2. This Fact Sheet contains information to …
Reimbursement for the Moderna COVID-19 Vaccine
www.modernatx.comcharge for administration. However, vaccination providers may seek appropriate reimbursement from a program or plan that covers COVID-19 vaccine administration fees for the vaccine recipient (private insurance, Medicare, Medicaid, HRSA COVID-19 Uninsured Program for non-insured recipients).
Moderna COVID-19 Vaccine EUA Letter of Authorization
www.modernatx.comJan 31, 2022 · vaccine in individuals 18 years of age or older who have undergone solid organ transplantation, or individuals 18 years of age or older who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise, FDA reviewed safety and effectiveness data reported in two manuscripts on solid organ transplant recipients.
Hoja informativa para receptores de la vacuna | EUA ...
www.modernatx.comLa vacuna contra la COVID-19 de Moderna es una vacuna no aprobada. En ensayos clínicos, aproximadamente 15,400 personas de 18 años en adelante han recibido al menos 1 dosis de la vacuna contra la COVID-19 de Moderna. Millones de personas han recibido la vacuna en virtud
Related documents
An Insider’s Guide to Clinical Study Reports
www.niche.org.ukclinical trial reports are prepared and provided to the regulatory agency(ies) as required by the applicable ... generally depends on the complexity of the study design and the size of the data package. It will also depend on the ... Interaction with the project team should provide a wider strategic understanding of the
ICH E9(R1) Estimands and Sensitivity Analysis in Clinical ...
database.ich.org8 Summary The addendum aims to improve the planning, design, analysis and interpretation of clinical trials. • Without a precise description of the trial objective and the treatment effect that is targeted for testing and estimation there is a risk that:
UNDERSTANDING CLINICAL TRIAL STATISTICS
oncologypro.esmo.orgUNDERSTANDING CLINICAL TRIAL STATISTICS. Prepared by Urania Dafni, Xanthi ... EaSt 6.3.1: a software package for the design and interim monitoring of group sequential clinical trials, Cytel Software Corporation, Cambridge, MA, ... Understanding Clinical Trials Statistics
Risk Assessment in Clinical Trials
www.ddismart.comshow-stopper risk, like no approval of clinical trial by an EC or IRB because of the placebo design of a trial. In such a case, the clinical trial plan should be reviewed and changed to avoid such a risk. It means probably eliminating such investigational sites from the clinical study plan.
ICH guideline E6 on good clinical practice
www.ema.europa.euQuality by design approaches should be applied across the clinical trial and supporting processes. 7.4. Strategies should be implemented to avoid, detect, and address serious non- compliance with GCP and prevent recurrence. 8- Clinical trial processes, measures, and approaches should be proportionate to the risks to
Understanding Clinical Trials - UKCRC
www.ukcrc.orgunderstanding of clinical research and to promote active patient and public ... possible trial. The design for the trial forms the basis of the trial protocol. 8 ... A clinical trial is often run in a number of different hospitals or health centres. The doctor or nurse who asks you to take part in
WHO R&D Blueprint novel Coronavirus
www.who.intthe design of the Pivotal Stage; and, to derive more precise estimates of patient ... clinical trial. It may be impossible to include a placebo for certain therapeutic ... Final decisions about eligibility would depend on additional understanding of the epidemiology and clinical characteristics of the disease, including a better ...